Delivery Order SPE2DB20D2014-SPE2DB25FC30Q
- Not listed
- The Defense Logistics Agency awarded a $6,530.16 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 mL pens on July 30, 2025, with an ultimate completion date of July 31, 2025. This non-competitive delivery order represents a single pharmaceutical product delivery executed under the company's existing contract vehicle with DLA. Mounjaro is a tirzepatide-based diabetes medication, consistent with AmerisourceBergen's extensive portfolio of...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,344.41 to AmerisourceBergen Drug Corp for the supply of Mounjaro 10 mg/0.5 mL pens on September 10, 2025, with completion expected by September 11, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a branded pharmaceutical product used in diabetes management,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,088.36 to AmerisourceBergen Drug Corp for the supply of Mounjaro (tirzepatide) 15 mg/0.5 mL pens on September 15, 2025. This firm fixed-price, non-set-aside delivery order, which is due for completion by September 16, 2025, represents a single transaction under AmerisourceBergen's larger pharmaceutical supply agreement with the federal government. The product will be delivered to AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $33,315.11 to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 mL pens (0.5 mL units). The contract is structured as a firm fixed-price delivery order with an ultimate completion date of August 13, 2025, and was competitively awarded without set-aside designations. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency awarded a delivery order valued at $6,724.34 to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 mL pens on July 2, 2025, with an ultimate completion date of July 3, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will...
- The Defense Logistics Agency awarded a delivery order valued at $40,974.26 to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 mL pens on August 28, 2025, with an ultimate completion date of August 29, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a diabetes medication that represents part of the broader pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,822.64 to AmerisourceBergen Drug Corp for the supply of Mounjaro 2.5 mg/0.5 mL pens on August 14, 2025, with an ultimate completion date of August 15, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a prescription medication...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $46,456.89 to AmerisourceBergen Drug Corp for the supply of Mounjaro 15 mg/0.5 mL pens. This firm fixed-price, competitively awarded delivery order was issued on September 9, 2025, with an ultimate completion date of September 10, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting AmerisourceBergen's competitive standing...
- The Defense Logistics Agency awarded a $3,537.17 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Mounjaro (tirzepatide) 5 mg/0.5 mL pens in 0.5 mL unit doses. The contract, which is a non-set-aside competitive award with an ultimate completion date of July 25, 2025, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a $1,904.63 delivery order to AmerisourceBergen Drug Corp for Mounjaro 15 mg/0.5 mL pens on May 5, 2025, with completion expected by May 6, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FC30QDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,348.42 to AmerisourceBergen Drug Corp for the supply of Mounjaro 10 mg/0.5 mL pens (0.5 mL units). This firm fixed-price delivery order, awarded on June 25, 2025, is set to conclude on June 26, 2025, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract utilizes no set-aside designation, indicating it was competitively awarded through open procurement channels. Mounjaro is a tirzepatide-based diabetes medication, reflecting the continued federal demand for specialized pharmaceutical products to support military and veteran healthcare systems. This delivery order is executed under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a child contract under this broader pharmaceutical prime vendor agreement, the delivery order exemplifies the company's role as a critical supplier within DLA's global pharmaceutical support network. AmerisourceBergen Drug Corp's federal contract portfolio demonstrates extensive capability in delivering a diverse range of brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains to support Department of Defense healthcare operations worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.3k | 6/25/25 |